Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata

Adults and adolescents with alopecia areata had nearly 8 times higher odds of near-complete scalp hair regrowth on an oral Janus kinase (JAK) inhibitor than on placebo, according to a systematic review and meta-analysis published in the American Journal of Clinical Dermatology.¹

A Crowded Drug Class Lacked Pooled Comparative Data

Alopecia areata affects roughly 2% of people at some point in their lives, with onset most common before age 40years, and generates an estimated 2.4 million US outpatient visits a year.²

Until baricitinib's 2022 approval, patients with extensive disease had few systemic options beyond off-label immunosuppressants, and the newer generation of oral JAK inhibitors that followed had only been tested against placebo in separate, differently designed trials.

The researchers searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials through November 2025 for randomized controlled trials of oral JAK inhibitors in patients 12 years and older with alopecia areata, a protocol registered in advance with PROSPERO. Topical JAK inhibitors, non-randomized studies, and subgroup-only analyses were excluded.¹

Twelve trials met the criteria, covering baricitinib, ritlecitinib, brepocitinib, deuruxolitinib, and ivarmacitinib, and 1 comparison of tofacitinib against azathioprine; 11 of the 12 trials included a placebo arm.

The pooled population totaled 4141 participants (n = 2558 women vs 1583 men; mean age, 35.8 years), with a mean baseline Severity of Alopecia Tool (SALT) score of 86.0 and a mean episode duration of 4.8 years.

JAK Inhibitors Outperformed Placebo Across Every Efficacy Threshold

At week 24, the odds of reaching a SALT score of 20 or less, indicating 80% or more scalp coverage, were nearly 8 times higher with a JAK inhibitor than placebo (OR, 7.99; 95% CI, 5.13-12.44).

The odds advantage grew by week 36, when patients on a JAK inhibitor had more than 9 times higher odds of reaching a SALT score of 10 or less than those on placebo (OR, 9.40; 95% CI, 4.58-19.29). Heterogeneity across trials was moderate for most endpoints, with I² values reaching as high as 67%.

Patients on a JAK inhibitor had higher odds of any adverse event than those on placebo (OR, 1.60; 95% CI, 1.33-1.94), but that elevated risk did not carry over to more serious outcomes: the odds of a serious adverse event (OR, 1.04; 95% CI, 0.69-1.57) or of discontinuing treatment because of an adverse event (OR, 1.22; 95% CI, 0.84-1.76) were not significantly different from placebo.

“The favourable safety profile of these agents is reassuring,” the researchers wrote.

Risk-of-Bias Concerns and Sparse Events Limit Certainty

Six of the 12 trials raised “some concerns” on the researchers' risk-of-bias assessment, largely because of missing outcome data and selective reporting of results. Estimates for serious and severe adverse events were also unstable, the researchers noted, because so few of these events occurred in any single trial.

Adolescent-specific evidence remains especially thin. Only 1 of the 12 trials enrolled adolescents, who made up just 15% of that trial's population, leaving clinicians with limited direct evidence to guide dosing or safety expectations in younger patients. The researchers called for head-to-head trials and longer pharmacovigilance data to clarify how the various oral JAK inhibitors compare with one another, not just with placebo.

For clinicians, the pooled data offer the clearest side-by-side look yet at how consistently this drug class outperforms placebo on regrowth, without the aggregate safety signal extending to serious harm. For payers managing formulary access across a growing list of approved and pipeline oral JAK inhibitors for alopecia areata, the absence of head-to-head comparative data means coverage decisions will likely continue to rest on individual trial results and price rather than on evidence of one agent's superiority over another.

References

1. Morriss S, Foo CH, Lin E, et al. Efficacy and safety of oral Janus kinase inhibitors in adults and adolescents with alopecia areata: a systematic review and meta-analysis of randomised controlled trials. Am J Clin Dermatol. 2026;27(5):925-943. doi:10.1007/s40257-026-01060-z
2. Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397-403. doi:10.2147/CCID.S53985